Shintaro Sakurai

Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase‐4 in patients with type 2 diabetes and non‐alcoholic fatty liver disease

Yoshimasa Aso, Kanako Kato, Shintaro Sakurai et al. · International Journal of Clinical Practice · 2019 · 97 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Clinical Study Comparing Bleeding and Nonbleeding Rectal Varices

Ryushi Shudo, Yasuyuki Yazaki, Shintaro Sakurai et al. · Endoscopy · 2002 · 59 citations

Medicine, Clinical Sciences, Internal Medicine +14

Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: Association with improvement of fibrinolysis

Shintaro Sakurai, Teruo Jojima, Toshie Iijima et al. · Journal of Diabetes and its Complications · 2020 · 37 citations

Medicine, Pharmacology, Pharmacotherapy +14

Genetic alteration of ARMC5 in a patient diagnosed with meningioma and primary macronodular adrenal hyperplasia: a case report

Teruo Jojima, Takahiko Kogai, Toshie Iijima et al. · European Journal of Endocrinology · 2020 · 26 citations

Life Sciences, Genetics, Molecular Genetics +16

Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes: Association with a slight increase in high-density lipoprotein cholesterol

Teruo Jojima, Shintaro Sakurai, Sho Wakamatsu et al. · International Journal of Cardiology · 2021 · 26 citations

Medicine, Endocrinology, Pharmacology +16